GO:1901624 negative regulation of lymphocyte chemotaxis: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901624 describes any process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte chemotaxis, a critical checkpoint in immune cell positioning [2, 5].
• Key negative regulators include the lipid phosphatase PTEN, which dephosphorylates PIP3 to oppose CXCR4-mediated chemotaxis, and the adaptor protein p66Shc, which restrains B-cell chemokine receptor signaling.
• Dysregulation of this process contributes to autoimmunity, chronic inflammation, and cancer immune evasion, as seen in primary atopic disorders and tumor microenvironment remodeling [1, 8].
• Viruses such as Epstein-Barr virus can hijack chemotaxis pathways, overriding negative regulation to promote aberrant B cell migration and diapedesis.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of negative regulators in lymphocyte migration [2, 5].
• Studying GO:1901624 requires integrated approaches including live imaging, chemotaxis assays, phosphoproteomics, and CRISPR library screening to identify novel brakes on lymphocyte motility [4, 8].
Description
Lymphocyte chemotaxis is the directed migration of T cells, B cells, and natural killer cells along chemical gradients, a process essential for immune surveillance and adaptive immunity [2, 5]. However, uncontrolled or misdirected migration can drive autoimmunity, chronic inflammation, and tumor immune evasion. To prevent such pathology, cells employ negative regulation of lymphocyte chemotaxis (GO:1901624), a biological process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte chemotaxis [2, 5]. This process acts as a molecular brake, ensuring that lymphocytes arrive at the right place at the right time and do not linger in tissues where they could cause damage [1, 8]. Research into GO:1901624 has revealed diverse mechanisms, from lipid phosphatase activity that degrades chemoattractant signals to adaptor proteins that dampen chemokine receptor signaling [2, 5]. For example, PTEN negatively regulates CXCR4-mediated chemotaxis by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), thereby opposing PI3K signaling. Similarly, p66Shc inhibits B-cell chemotaxis by interfering with chemokine receptor signaling cascades. These findings underscore the importance of negative regulation in maintaining immune homeostasis and preventing disease. Understanding GO:1901624 is critical for immunologists, cancer biologists, and clinicians. Defects in negative regulation can lead to primary atopic disorders, where genomic sequencing has identified mutations in immune regulatory genes. In cancer, negative regulators such as BCAT2 shape a noninflamed tumor microenvironment by suppressing proinflammatory chemokines, thereby reducing lymphocyte infiltration and promoting resistance to anti-PD-1/PD-L1 immunotherapy. Thus, targeting negative regulation of lymphocyte chemotaxis holds therapeutic potential for boosting antitumor immunity or dampening autoimmune responses [1, 8].
negative regulation of lymphocyte chemotaxis At A Glance
| GO ID | GO:1901624 |
|---|---|
| GO term | negative regulation of lymphocyte chemotaxis |
| Ontology | biological_process |
| Synonym | down regulation of lymphocyte chemotaxis, down-regulation of lymphocyte chemotaxis, downregulation of lymphocyte chemotaxis, inhibition of lymphocyte chemotaxis |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of lymphocyte chemotaxis |
| Key negative regulators | PTEN, p66Shc, BCAT2, and others [2, 5, 8] |
| Associated diseases | Primary atopic disorders, cancer immune evasion, chronic inflammation [1, 8] |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, chemotaxis assays, live imaging [2, 4, 5] |
What Is GO:1901624?
Negative regulation of lymphocyte chemotaxis (GO:1901624) is any biological process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte chemotaxis. In other words, it encompasses molecular events that put the brakes on the directed movement of lymphocytes toward chemical signals, ensuring that immune cell migration is tightly controlled [2, 5].
Why Is negative regulation of lymphocyte chemotaxis Important in Cell Biology?
Negative regulation of lymphocyte chemotaxis is essential for immune homeostasis because it prevents excessive or misdirected lymphocyte migration that can lead to tissue damage, autoimmunity, and chronic inflammation [1, 2]. In cancer, the ability of tumors to suppress lymphocyte chemotaxis contributes to immune evasion and resistance to immunotherapy, making this process a key target for therapeutic intervention. Moreover, pathogens such as Epstein-Barr virus can manipulate chemotaxis pathways to enhance B cell migration and dissemination, highlighting the clinical relevance of understanding these regulatory mechanisms.
• Prevents autoimmune pathology by limiting lymphocyte infiltration into healthy tissues.
• Controls chronic inflammatory diseases by dampening excessive immune cell recruitment.
• Regulates antitumor immunity; loss of negative regulation can enhance lymphocyte infiltration and improve immunotherapy responses.
• Modulates B cell trafficking and germinal center responses, impacting antibody production.
• Influences viral pathogenesis, as EBV exploits chemotaxis pathways for B cell dissemination.
• Provides targets for therapeutic modulation in allergy, autoimmunity, and cancer [1, 8].
• Helps maintain lymphocyte homeostasis and prevent lymphoproliferative disorders.
• Guides development of precision medicine approaches for primary atopic disorders.
• Informs vaccine design by controlling lymphocyte localization to lymphoid organs.
• Offers insights into basic mechanisms of cell migration and signal transduction [2, 5].
What Happens During negative regulation of lymphocyte chemotaxis?
Initiation of negative regulation by lipid phosphatases
In simple terms: Enzymes like PTEN act as brakes by destroying the chemical signal that tells lymphocytes to move.
Negative regulation of lymphocyte chemotaxis often begins with lipid phosphatases that degrade chemoattractant-induced second messengers. PTEN (phosphatase and tensin homolog) dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (4,5)-bisphosphate (PIP2), thereby opposing PI3K signaling and inhibiting CXCR4-mediated chemotaxis. This lipid phosphatase activity is a primary mechanism for stopping lymphocyte migration toward CXCL12.
Adaptor protein-mediated inhibition of chemokine receptor signaling
In simple terms: Proteins like p66Shc interfere with the internal communication of chemokine receptors, reducing the cell's ability to respond to attractants.
Adaptor proteins such as p66Shc negatively regulate chemokine receptor signaling and B-cell chemotaxis. p66Shc inhibits chemokine-induced activation of Rac and AKT, thereby reducing B cell migration toward CXCL12 and CXCL13. This regulation is critical for preventing excessive B cell recruitment into lymphoid follicles and tissues.
Metabolic and transcriptional control of chemokine production
In simple terms: Metabolic enzymes can change the tumor environment by reducing the production of signals that attract lymphocytes.
BCAT2 (branched-chain amino acid transaminase 2) shapes a noninflamed tumor microenvironment by negatively regulating proinflammatory chemokines and anticancer immunity. Loss of BCAT2 increases chemokine expression and enhances lymphocyte infiltration, indicating that BCAT2 suppresses chemotaxis indirectly by limiting chemoattractant availability.
Viral modulation of chemotaxis pathways
In simple terms: Some viruses can override the brakes on lymphocyte movement to help infected cells spread.
Epstein-Barr virus (EBV) induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways, effectively bypassing negative regulation. EBV infection alters the balance of chemotactic signals, promoting B cell dissemination and potentially contributing to EBV-associated malignancies.
Integration with purinergic signaling
In simple terms: ATP and related molecules can fine-tune lymphocyte movement, adding another layer of control.
Purinergic signaling regulates airway inflammation and can modulate lymphocyte chemotaxis. Extracellular ATP and adenosine act on purinergic receptors to either promote or inhibit lymphocyte migration, depending on the receptor subtype and context. This crosstalk provides additional checkpoints for negative regulation.
Key Genes Involved in GO:1901624 negative regulation of lymphocyte chemotaxis
The following genes and proteins are central to the negative regulation of lymphocyte chemotaxis, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTEN | Lipid phosphatase that dephosphorylates PIP3, opposing CXCR4-mediated chemotaxis | Tumor suppressor; frequently mutated in cancers; target for enhancing antitumor immunity |
| p66Shc | Adaptor protein that inhibits chemokine receptor signaling and B-cell chemotaxis | Regulates B cell migration; implicated in autoimmune and inflammatory diseases |
| BCAT2 | Metabolic enzyme that negatively regulates proinflammatory chemokines and anticancer immunity | Shapes noninflamed tumor microenvironment; resistance to anti-PD-1/PD-L1 therapy |
| CXCR4 | Chemokine receptor whose signaling is negatively regulated by PTEN | Target for blocking lymphocyte recruitment in autoimmunity and cancer |
| CCR8 | Chemokine receptor expressed on Tregs and tumor cells; prognostic in GIST | Potential target for cancer immunotherapy; marker of poor prognosis |
| FAK | Kinase involved in EBV-induced B cell migration and diapedesis | Mediates viral hijacking of chemotaxis; target for antiviral strategies |
| B7-H1 (PD-L1) | Immune checkpoint protein; independent predictor of poor prognosis in NSCLC | Linked to immune evasion; may influence lymphocyte infiltration |
| B7-H3 | Immune checkpoint protein; independent predictor of poor prognosis in NSCLC | Modulates T cell responses; potential therapeutic target |
| P2RY receptors | Purinergic receptors that modulate lymphocyte chemotaxis | Regulate airway inflammation; drug targets for asthma and COPD |
| Adenosine receptors | Mediate purinergic suppression of lymphocyte migration | Involved in tissue protection and immunosuppression |
| PI3K | Kinase that generates PIP3; opposed by PTEN | Central to chemokine signaling; target for immunomodulation |
| Rac | Small GTPase activated by chemokine receptors; inhibited by p66Shc | Regulates actin cytoskeleton during migration |
| AKT | Serine/threonine kinase downstream of PI3K; inhibited by p66Shc | Promotes cell survival and migration; target in cancer |
| CXCL12 | Chemokine ligand for CXCR4; its gradient is regulated by PTEN | Controls lymphocyte homing; involved in autoimmunity |
| CXCL13 | Chemokine ligand for CXCR5; B cell chemotaxis regulated by p66Shc | Organizes lymphoid follicles; implicated in autoimmunity |
| EBV proteins | Viral factors that induce FAK-dependent chemotaxis | Model for viral pathogenesis and B cell transformation |
| PTEN-induced kinase 1 (PINK1) | Mitochondrial kinase; may influence lymphocyte migration via metabolic regulation | Potential link between metabolism and chemotaxis |
| SHC1 | Gene encoding p66Shc adaptor protein | Genetic models for B cell migration and autoimmunity |
How Is negative regulation of lymphocyte chemotaxis Regulated?
Negative regulation of lymphocyte chemotaxis is itself tightly regulated at multiple levels. PTEN activity is controlled by phosphorylation, ubiquitination, and subcellular localization, allowing rapid responses to changes in the microenvironment. p66Shc is regulated by oxidative stress and phosphorylation, which modulate its inhibitory effect on chemokine receptors. Metabolic enzymes such as BCAT2 are influenced by nutrient availability and oncogenic signaling, thereby indirectly controlling chemokine production and lymphocyte recruitment. Additionally, purinergic signaling pathways integrate extracellular ATP and adenosine levels to fine-tune lymphocyte migration. These layers of regulation ensure that lymphocyte chemotaxis is appropriately dampened when necessary.
negative regulation of lymphocyte chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Cancer, autoimmunity; loss enhances chemotaxis | PTEN knockout T cells; chemotaxis assays |
| p66Shc | B cell autoimmunity; inhibits chemokine signaling | p66Shc knockout mice; B cell migration assays |
| BCAT2 | Cancer immune evasion; resistance to anti-PD-1 | BCAT2 knockout tumor cells; syngeneic mouse models |
| CXCR4 | Autoimmune diseases; mediates chemotaxis | CXCR4 point-mutant knock-in mice |
| CCR8 | Gastrointestinal stromal tumors; poor prognosis | CCR8 overexpression in GIST cell lines |
Primary atopic disorders and immune dysregulation
Primary atopic disorders (PAD) are a group of inherited conditions characterized by severe allergic inflammation, often due to mutations in genes that regulate immune cell migration and activation. Rapid identification of PAD by clinical landmark-guided genomic sequencing has revealed defects in negative regulators of lymphocyte chemotaxis, leading to excessive lymphocyte infiltration into skin and airways. Understanding these genetic lesions helps tailor targeted therapies and improves patient outcomes.
Cancer immune evasion and immunotherapy resistance
Tumors can evade immune destruction by suppressing lymphocyte chemotaxis. BCAT2 negatively regulates proinflammatory chemokines, creating a noninflamed tumor microenvironment that resists anti-PD-1/PD-L1 immunotherapy. Similarly, expression of immune checkpoint proteins B7-H1 and B7-H3 in non-small cell lung cancer is associated with poor prognosis, potentially by limiting T cell infiltration. Targeting negative regulators of chemotaxis could convert cold tumors to hot, enhancing immunotherapy efficacy.
Viral pathogenesis and B cell malignancies
Epstein-Barr virus (EBV) induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways, overriding normal negative regulation. This promotes viral dissemination and may contribute to EBV-associated lymphomas. Understanding how EBV manipulates chemotaxis could lead to new antiviral or antilymphoma strategies.
Chronic inflammatory airway diseases
Purinergic regulation of airway inflammation involves modulation of lymphocyte chemotaxis. Dysregulated purinergic signaling can lead to excessive lymphocyte recruitment into the lungs, exacerbating asthma and COPD. Therapeutic targeting of purinergic receptors may restore negative regulation and reduce inflammation.
From negative regulation of lymphocyte chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PTEN enhance lymphocyte chemotaxis? | PTEN knockout Jurkat or primary T cells; CXCL12 gradient assays |
| How does p66Shc inhibit B cell chemotaxis? | p66Shc knockout mice; B cell chemotaxis to CXCL12/CXCL13 |
| Can BCAT2 deletion boost antitumor immunity? | BCAT2 knockout tumor cells in syngeneic mice; anti-PD-1 treatment |
| What is the role of FAK in EBV-induced migration? | FAK knockout B cells; EBV infection; diapedesis assays |
| Does CCR8 expression correlate with GIST prognosis? | CCR8 overexpression in GIST cell lines; xenograft models |
| Can purinergic receptors modulate airway lymphocyte recruitment? | P2RY knockout mice; allergic airway inflammation models |
How to Study the negative regulation of lymphocyte chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Number of migrated cells toward chemokine | Screening negative regulators in lymphocytes [2, 5] |
| Microfluidic chemotaxis chip | Directionality, speed, and persistence of migration | Live imaging of chemokine gradient sensing |
| Phosphoproteomics | Global phosphorylation changes | Identifying signaling nodes inhibited by p66Shc |
| CRISPR knockout screen | Genes whose loss alters chemotaxis | Discovery of novel negative regulators |
| Intravital two-photon microscopy | Real-time migration in tissues | B cell follicle entry and egress |
| Flow cytometry-based migration assay | Frequency of migrated cell subsets | Quantifying Treg vs effector T cell chemotaxis |
| ELISA for chemokines | Concentration of chemokines in supernatant | Assessing BCAT2-mediated chemokine suppression |
| Western blot for PTEN/p66Shc | Protein expression and phosphorylation | Validating knockout or overexpression models [2, 5] |
Live-cell imaging and chemotaxis assays
Live-cell imaging using microfluidic devices or transwell assays allows real-time visualization of lymphocyte migration toward chemokine gradients. These methods quantify speed, directionality, and frequency of chemotaxis, enabling assessment of negative regulators such as PTEN and p66Shc [2, 5]. Combining with fluorescent reporters for PIP3 or Rac activation provides mechanistic insights.
Phosphoproteomics and signaling analysis
Phosphoproteomics can identify changes in phosphorylation events downstream of chemokine receptors upon modulation of negative regulators. For example, p66Shc knockout B cells show altered AKT and Rac phosphorylation. Mass spectrometry-based approaches reveal global signaling rewiring and potential feedback loops.
CRISPR screening for novel regulators
Genome-wide CRISPR knockout or activation screens coupled with chemotaxis assays can identify genes whose loss or overexpression alters lymphocyte migration. Such screens have uncovered metabolic enzymes like BCAT2 that indirectly regulate chemokine production. Libraries targeting kinases, phosphatases, and adaptor proteins are particularly useful [2, 5].
In vivo adoptive transfer and intravital imaging
Adoptive transfer of labeled lymphocytes into recipient mice followed by intravital two-photon microscopy allows study of migration in native tissues. This approach has been used to show that p66Shc deficiency increases B cell entry into follicles. It provides physiological relevance and spatial context [2, 4].
How CRISPR Can Be Used to Study GO:1901624 negative regulation of lymphocyte chemotaxis
Knockout
CRISPR knockout of negative regulators such as PTEN or p66Shc in lymphocyte cell lines or primary cells enables loss-of-function studies. PTEN knockout increases CXCR4-mediated chemotaxis, confirming its role as a brake. p66Shc knockout enhances B cell migration toward CXCL12 and CXCL13. These models are essential for validating gene function in chemotaxis.
Point Mutation
Point mutations can dissect specific domains or catalytic activities. For example, a phosphatase-dead PTEN mutant (C124S) can be knocked into cells to test whether lipid phosphatase activity is required for inhibiting chemotaxis. Similarly, phosphorylation-site mutants of p66Shc can reveal regulatory mechanisms.
Knock-in
Knock-in of tagged or reporter versions of negative regulators allows real-time tracking and interaction studies. A GFP-PTEN knock-in can visualize its localization during chemotaxis. Knock-in of mutant CXCR4 or CCR8 can model disease-associated variants and their impact on negative regulation.
Overexpression
Overexpression of negative regulators such as PTEN or p66Shc can suppress chemotaxis, providing gain-of-function evidence. Overexpressing BCAT2 in tumor cells reduces chemokine production and lymphocyte infiltration, modeling an immune-cold microenvironment. These models are useful for testing therapeutic strategies to enhance or inhibit chemotaxis.
How EDITGENE Supports negative regulation of lymphocyte chemotaxis Research
Researchers studying negative regulation of lymphocyte chemotaxis-related genes often need to determine whether a candidate gene is causally involved in restraining lymphocyte migration, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from generating knockout and point-mutation cell lines to performing genome-wide screens and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lymphocyte chemotaxis research.
Frequently Asked Questions About negative regulation of lymphocyte chemotaxis
What is negative regulation of lymphocyte chemotaxis?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of lymphocyte chemotaxis, ensuring that immune cells do not migrate excessively or to inappropriate locations [2, 5].
What genes are involved in negative regulation of lymphocyte chemotaxis?
Key genes include PTEN, which dephosphorylates PIP3 to inhibit CXCR4 signaling, p66Shc, which dampens B cell chemokine receptor signaling, and BCAT2, which suppresses proinflammatory chemokines.
How does PTEN negatively regulate lymphocyte chemotaxis?
PTEN acts as a lipid phosphatase that converts PIP3 to PIP2, thereby opposing PI3K signaling and reducing CXCR4-mediated chemotaxis toward CXCL12.
What is the role of p66Shc in B cell chemotaxis?
p66Shc inhibits chemokine receptor signaling and B cell chemotaxis by interfering with Rac and AKT activation, preventing excessive B cell recruitment.
Can viruses manipulate negative regulation of lymphocyte chemotaxis?
Yes, Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent pathways, effectively overriding normal negative regulation.
How is negative regulation of lymphocyte chemotaxis linked to cancer?
Tumors can evade immunity by suppressing lymphocyte chemotaxis; for example, BCAT2 creates a noninflamed microenvironment and resistance to anti-PD-1/PD-L1 therapy. Checkpoint proteins like B7-H1 and B7-H3 also predict poor prognosis.
What experimental models are used to study negative regulation of lymphocyte chemotaxis?
Common models include CRISPR knockout mice or cell lines for PTEN, p66Shc, and BCAT2, combined with transwell chemotaxis assays, live imaging, and phosphoproteomics [2, 5, 8].
What diseases are associated with defective negative regulation of lymphocyte chemotaxis?
Defects can lead to primary atopic disorders, chronic inflammatory airway diseases, and cancer immune evasion.
How can CRISPR screening help identify new regulators of lymphocyte chemotaxis?
Genome-wide CRISPR screens coupled with chemotaxis assays can uncover novel genes whose loss enhances or suppresses migration, revealing new negative regulators.
What services does EDITGENE offer for studying negative regulation of lymphocyte chemotaxis?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics analysis to dissect chemotaxis regulatory networks [2, 5, 8].
Conclusion
Negative regulation of lymphocyte chemotaxis (GO:1901624) is a vital biological process that restrains immune cell migration to prevent autoimmunity, chronic inflammation, and cancer immune evasion. Key regulators such as PTEN, p66Shc, and BCAT2 have been identified through decades of research, revealing diverse mechanisms from lipid phosphatase activity to metabolic control of chemokine production [2, 5, 8]. Dysregulation of this process contributes to primary atopic disorders, viral pathogenesis, and resistance to immunotherapy [1, 4, 8]. Continued investigation using CRISPR-based models, advanced imaging, and multi-omics approaches will uncover additional layers of regulation and therapeutic opportunities. EDITGENE stands ready to support these efforts with tailored CRISPR services, from knockout to library screening, empowering researchers to translate discoveries into clinical benefit.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Patrussi L et al.. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.. Cell Death Dis 5(2):e1068 PMID: 24556683
- 3. Mao Y et al.. 2015. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.. Oncotarget 6(5):3452-61 PMID: 25609202
- 4. Delecluse S et al.. 2025. Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways.. Nat Commun 16(1):4581 PMID: 40389409
- 5. Gao P et al.. 2005. Negative regulation of CXCR4-mediated chemotaxis by the lipid phosphatase activity of tumor suppressor PTEN.. Blood 106(8):2619-26 PMID: 15994292
- 6. Li HL et al.. 2020. Clinical and prognostic significance of CC chemokine receptor type 8 protein expression in gastrointestinal stromal tumors.. World J Gastroenterol 26(31):4656-4668 PMID: 32884223
- 7. Koeppen M et al.. 2011. Purinergic regulation of airway inflammation.. Subcell Biochem 55:159-93 PMID: 21560048
- 8. Cai Z et al.. 2023. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.. Adv Sci (Weinh) 10(8):e2207155 PMID: 36642843
